18 Jan, 2022

my mhealth appoints biotech veteran and digital therapeutics pioneer, Joel Sangerman FABC, as Chief Commercial Officer

my mhealth, a global leader in delivering clinically proven digital health programs, announced today the appointment of biotech industry veteran and digital therapeutic pioneer, Joel Sangerman FABC as Chief Commercial Officer to expand its rapidly growing user base in the United States. Previously Mr. Sangerman served as Chief Commercial Officer for Click Therapeutics, VP of Market Development for Walgreens, & Director of Reimbursement for Johnson & Johnson.

Simon Bourne, CEO and co-founder said,

"Joel was adamant that we ensure our health economic evidence was crystal clear before agreeing to lead our financing and commercial efforts in the US. That time is now as the US market is embracing the fact that digital therapeutics, because of their behavioral focus, makes every other intervention work better. We are ecstatic about tapping Joel’s vast experience in US reimbursement and commercial affairs to accelerate the US adoption of my mhealths digital therapeutics"

Sangerman stated,

"If the myCOPD digital therapeutic was an FDA approved drug, it would be an absolute blockbuster. I’m excited to lead the US launch and replicate with our CMS and private insurers what the UK’s National Health Service has achieved using myCOPD to improve outcomes and scale COPD interventions at a population level."

If you’d like to find out more about the awarding my mhealth digital therapeutic platform for COPD, diabetes, asthma and cardiac disease get in touch here or call us on +44 (0)1202 299 583.

---

Topics

Awards appointments Health tech Digital Therapeutics US expansion Digital health

---

Further information

Email: info@mymhealth.com
Call: +44 (0)1202 299 583

---